Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
6 m' ^. \- V$ [0 @& _6 t
) v& R, d: O: Z7 F! W0 j) |% O, U) k& c
Sub-category:
" {! N# V% G& o% sMolecular Targets , N) Z3 @, M( G% g5 G# [
; T f6 W2 g" F. ?9 X' k
2 U% E, D% K- v6 E3 X2 j) XCategory:0 i+ t- p( m. w- p8 A3 @/ a& ]1 ]1 \
Tumor Biology
* t( d( L6 B( q8 m9 Z
5 o7 W* A; m4 z1 ]4 P# u, d1 D8 ?8 _ p) C$ M' O- t
Meeting:% w5 G' M! v$ ~5 t; I- C" V$ w# |5 E
2011 ASCO Annual Meeting ! T& f2 V: D: E' f/ Y- n1 D
( d9 N1 u# }! g' u6 Y0 P3 k
5 G, `8 q3 E& h- u" ]. [4 ]2 CSession Type and Session Title:* {& {! z$ Q X4 ]5 _
Poster Discussion Session, Tumor Biology & t3 A7 s% f+ s- t0 @, _0 ]) @, F
+ o! J3 v/ P0 d
' `" ^' a2 \4 h; A5 Q
Abstract No:5 R& W+ u. u1 j$ F' M2 A
10517 / m8 U; C+ {( Q+ q* h4 n% N/ U
; E3 {6 }5 i- y! G) c; ~+ s! V/ J/ Q& i2 s% |, ^* M( g
Citation:" m k$ ]3 F$ b/ x% p" D
J Clin Oncol 29: 2011 (suppl; abstr 10517)
9 |4 n$ z7 M' k( w8 J) F5 I8 `
0 f- z! h) u/ u: M! o/ Q
- B) C( Y& v' P$ eAuthor(s):
" c# ~0 m2 X# z: YJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 ~5 I! w0 f1 t* K: C3 g
1 f4 A* e" i$ p& D; @ V) q, r1 ~( p! |! b: f
6 c8 {2 \ A8 L" u& m. e! w
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# r( a0 ?5 J( z, y$ [
8 c% n- q# @( y1 }6 mAbstract Disclosures
" j* ^9 ]; [. V( [" ?+ a8 j* O# J; ^) P: M
Abstract:
9 m: I8 }3 E0 t3 {' j$ F" f2 _
# S* n0 R0 |- K1 T9 u: L% K: D
$ U! w2 }8 i. m; yBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- i2 Q5 |" a9 t6 l2 v* N z; b
' P: D' m* r- r; e# Z
- d" Y; a3 |: O9 ~# E; [$ C |
" }+ }0 a/ i' U
显身卡
